ALK and non-small cell lung carcinoma: In another study, ALK rearrangements were identified in the ctDNA of 19 out of 24 ALK+ NSCLC patients [89]; longitudinal follow-up showed that ctDNA detection correlated with disease progression and the authors could identify ALK mutations in plasma post-crizotinib.